Druggability & Clinical Context
Druggability
Medium
Score: 0.49
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
25
Known Drugs:
3
Approved:
3
In Clinical Trials:
0
Drug Pipeline (3 compounds)
3 Approved
Therapeutic Areas:Oncology/Cancer (microtubule-targeting chemotherapy) Neurodegenerative diseases (Alzheimer's, Parkinson's) Peripheral neuropathy and axonal transport disorders Cortical dysplasia and developmental neurological disorders Neuroinflammation and neurodegeneration
Druggability Rationale: TUBB3 exhibits high druggability (0.90 score) due to extensive structural characterization (25 PDB structures, 1.8ร
resolution), a well-defined microtubule binding pocket validated by three approved taxane drugs, and the target's role as a structural protein with established small-molecule stabilizer mechanisms. The availability of cryo-EM data and AlphaFold models further supports rational drug design and optimization.
Mechanism: Small molecule stabilizers of microtubule structure or assembly
Drug Pipeline (3 compounds)
3 Approved
Known Drugs:Paclitaxel (approved) โ Cancer
Docetaxel (approved) โ Cancer
Cabazitaxel (approved) โ Cancer
Structural Data:PDB (25) โAlphaFold โCryo-EM โ
Binding Pocket Analysis:The taxane binding pocket is located at the interface between ฮฑ- and ฮฒ-tubulin within the microtubule lattice, characterized by a hydrophobic cleft stabilized by residues in the M-loop region; this allosteric pocket accommodates stabilizing agents that prevent microtubule depolymerization and promote dynamics necessary for axonal transport and neuronal function.
Selectivity & Safety Considerations
Selectivity remains a significant challenge given TUBB3's structural similarity to other ฮฒ-tubulin isoforms (TUBB, TUBB2A, TUBB2B); achieving isoform-selective inhibition is difficult and off-target effects on ubiquitous tubulin isoforms may limit neurological applications. However, TUBB3's neuron-specific expression provides a therapeutic window for CNS-focused development over peripheral tissues.
Clinical Trials (8)
Relevant trials from ClinicalTrials.gov
By Phase
PHASE1: 1 ยท PHASE2: 4 ยท PHASE3: 3
PHASE3
NCT06470243
n=528
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Cabazitaxel
Sponsor: SWOG Cancer Research Network | Started: 2024-11-27
PHASE1
NCT05819892
n=21
Endometrial Cancer
Interventions: Paclitaxel, Carboplatin, Dostarlimab
Sponsor: M.D. Anderson Cancer Center | Started: 2023-07-17
PHASE2
NCT07432594
n=82
High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer
Interventions: Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sc | Started: 2026-03-01
PHASE2
NCT04622761
n=120
Prostate Cancer
Interventions: Cabazitaxel
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust | Started: 2021-01-15
PHASE3
NCT03705429
n=51
Breast Neoplasms
Interventions: TC-H x Paclitaxel (P) + Trastuzumab(T)
Sponsor: London Health Sciences Centre Research Institute OR Lawson R | Started: 2019-05-01
PHASE3
NCT00196872
n=3000
Breast Cancer
Interventions: Epirubicine, Cyclophosphamide, Taxol
Sponsor: GBG Forschungs GmbH | Started: 2004-07
PHASE2
NCT00511992
n=20
Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma
Interventions: Avastin, Paclitaxel, Cisplatin
Sponsor: University of Oklahoma | Started: 2007-07
PHASE2
NCT00087165
n=22
Prostate Cancer
Interventions: GTI-2040, docetaxel, prednisone
Sponsor: University Health Network, Toronto | Started: 2005-01